Miljöpåverkan
Eliglustat
Miljörisk:
Risk för miljöpåverkan av eliglustat kan inte uteslutas då ekotoxikologiska data saknas.
Nedbrytning:
Det kan inte uteslutas att eliglustat är persistent, då data saknas.
Bioackumulering:
Eliglustat har låg potential att bioackumuleras.
Läs mer
Detaljerad miljöinformation
Environmental Risk Classification
Predicted Environmental Concentration (PEC)
PEC is calculated according to the following formula:
PEC (µg/L) = (A*109*(100-R))/(365*P*V*D*100) = 1.37*10-6*A*(100-R)
PEC = 1,88*10-5 µg/L
Where:
A = 0,1371 kg (total sold amount API in Sweden year 2023, data from IQVIA)
R = 0 % removal rate (due to loss by adsorption to sludge particles, by volatilization, hydrolysis or biodegradation)
P = number of inhabitants in Sweden = 10*106
V (L/day) = volume of wastewater per capita and day = 200 (ECHA default) (Ref. I)
D = factor of dilution of waste water by surface water flow = 10 (ECHA default) (Ref. I)
According to the European Medicines Agency guideline on environmental risk assessment of medicinal products (EMA/CHMP/SWP/4447/00), use of eliglustat is unlikely to represent a risk for the environment, because the predicted environmental concentration (PEC) at the time of registration was below the action limit 0.01 µg/L.
Predicted No Effect Concentration (PNEC)
Ecotoxicological studies
No data available.
Environmental risk classification (PEC/PNEC ratio)
Since it is not possible to calculate the environmental risk classification (PEC/PNEC ratio), the summary phrase for the environmental risk is:
"Risk of environmental impact of eliglustat cannot be excluded, since no ecotoxicity data are available."
Degradation
No data available.
Therefore, the summary phrase for degradation to be used is:
”The potential for persistence of eliglustat cannot be excluded, due to lack of data”.
Bioaccumulation
Partitioning coefficient
Log Kow = 2.84 (potentiometric method, pH unknown)
(Ref. II).
Justification of chosen bioaccumulation phrase:
Since log Kow < 4, eliglustat has low potential for bioaccumulation
(Ref. II).
Excretion (metabolism)
Eliglustat is extensively metabolized with high clearance, mainly by CYP2D6 and to a lesser extent CYP3A4. Primary metabolic pathways of eliglustat involve sequential oxidation of the octanoyl moiety followed by oxidation of the 2,3-dihydro-1,4-benzodioxane moiety, or a combination of the two pathways, resulting in multiple oxidative metabolites.
After oral administration, the majority of the administered dose is excreted in urine (41.8 %) and faeces (51.4 %), mainly as metabolites.
(Ref. III)
References
-
ECHA, European Chemicals Agency. 2008 Guidance on information requirements and chemical safety assessment, find here.
-
Cerdelga - Assessment report for an initial marketing authorisation application. 20 November 2014. Retrieved November 17, 2021 from EMA, find here.
-
SmPC of Cerdelga. Retrieved November 17, 2021 from EMA, find here.